Pds biotech to host company conference call following oral presentation of pds0101 data at 2021 asco annual meeting

Florham park, n.j., may 24, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, today announced that they will host a company conference call on june 8, 2021 at 8:00 am et, following the oral presentation of preliminary data of pds0101 at the 2021 american society of clinical oncology (asco) annual meeting. a press release summarizing the abstract data was issued on may 20.
PDSB Ratings Summary
PDSB Quant Ranking